Cell culture plates market seen reaching $3.09B by 2030

The cell culture plates market is projected to grow from $2.29 billion in 2025 to $3.09 billion by 2030, driven by biomedical research, chronic disease studies and broader use of automated lab workflows. North America held the largest regional share in 2025 as demand rises for laboratory tools used in drug development and disease modeling.

Why it matters: - Cell culture plates are core tools for biomedical research, pharmaceutical testing and cell-based assays. - Growth in chronic disease research and regenerative medicine is expanding demand for standardized lab consumables. - The market outlook points to steady demand for products that support drug development, precision medicine and automated workflows.

What happened: - The Business Research Company released a 2026 report on the global cell culture plates market. - The market is estimated at $2.29 billion in 2025 and is forecast to reach $2.44 billion in 2026. - The report projects the market will grow to $3.09 billion by 2030. - The report pegs the market’s forecast CAGR at 6.1% through 2030. - North America held the largest share of the market in 2025.

The details: - Historical growth from 2025 to 2026 reflects broader biomedical research, higher spending on pharmaceutical R&D, more use of in vitro testing models and wider adoption of cell-based assays. - Forecast growth is tied to demand for advanced cell culture models, investment in regenerative medicine, expansion of biopharmaceutical manufacturing and stronger use of precision medicine research. - The report defines cell culture plates as flat, low-bottomed laboratory tools used to cultivate bacteria, molds and cells in controlled conditions. - Cell culture plates help researchers study disease progression, optimize cell growth, test therapies and evaluate drug efficacy. - The report cites rising chronic disease prevalence as a key demand driver. - In June 2024, the National Health Service in the UK reported 3,615,330 registered patients diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The report’s growth case suggests the market is benefiting less from a single product shift and more from a broader increase in research intensity across life sciences. - North America’s lead implies established research infrastructure and higher lab spending continue to anchor demand. - The chronic-disease reference reinforces how disease burden is translating into more preclinical and translational research.

What's next: - The market is expected to keep expanding through 2030 as biopharma, regenerative medicine and automated lab systems scale up. - Regional competition may intensify as the report highlights opportunity across multiple global markets, not just North America. - More lab workflows are likely to shift toward standardized, high-throughput cell culture formats as research demand grows.

The bottom line: - Cell culture plates remain a small but essential part of a larger life sciences growth cycle, with sustained demand expected through the end of the decade.